| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Citi |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2011-06-15 08:40:45 |
| Versijas komentārs | |
| Teksts |
“Grindeks” informs that the XXIII Nordic-Baltic Congress of Cardiology will be held in Riga, the Radisson Blu hotel, 16 – 18 June 2011, which is one of the most significant events in the medical field of cardiology in Latvia, which brings together more than 800 cardiologists from around 30 countries worldwide. Local pharmaceutical company “Grindeks” has become a silver sponsor and in the framework of the congress will organize a symposium “Energetic metabolism corrector role in the treatment of the coronary heart disease”. In the symposium scientific reading will be performed by prof. Andrejs Erglis, academician of Latvian Academy of Sciences prof. Ivars Kalvins and dr. med. Vilnis Dzerve. According to the study on heart health status of the
inhabitants of Latvia enforced by the Research Institute of
Cardiology, University of Latvia and the Latvian Innovative
Medicine Foundation, mortality from cardiovascular or coronary
disease remains above 53% of all deaths in Latvia. The situation is
similar also in other Baltic and CIS countries. For example, in
Lithuania, the death rate from heart disease is the same as in
Latvia, but in Russia - more than 57%.
The main cause of coronary heart disease is the
deposition of cholesterol in the coronary artery wall,
as a result the blood vessels become rigid, its diameter decreases,
the blood supply to the heart is hindered and consequently, the
heart receives less oxygen. The whole-body blood circulation is
hindered, as the changes affect not only the heart but also other
blood vessels. Coronary heart disease may manifest as angina,
myocardial infarction, sudden death, arrhythmias.
Therefore, heart disease prevention and
treatment is very important in maintaining and improving quality of
life of each person. In its turn, energetic metabolism
correctors or metabolic medications are highly effective in the
treatment of coronary heart disease, as they have a positive effect
on the body's energetic metabolism, which restores oxygen supply
and consumption process balance.
On
“Grindeks”
“Grindeks” is the leading pharmaceutical company in the
Baltic States. Its main fields of action are: research,
development, manufacturing and sale of original products, generics
and active pharmaceutical ingredients. “Grindeks” specializes in
the heart and cardiovascular, CNS and anti-cancer medication
therapeutic groups.
A range of “Grindeks’s”
products covers a successful combination of original products and
generics, with the original products
Mildronate® and
Ftorafur® and more than 100 forms of
effective and safe generics included therein.
The Group consists of four subsidiary companies in
Latvia, Estonia and Russia, as well representative offices in ten
countries. Products of the company are exported to 50 countries and
its export comprises more than 95% of the total turnover. The main
markets are: Russia and other CIS countries, the Baltic
States, Germany and the
Netherlands. JSC “Grindeks” shares are listed in the
Official List of “NASDAQ
OMXRiga”.
Further information on the company –
www.grindeks.lv
Further information:
Laila Klavina
Head of the Communications Department
JSC “Grindeks”
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
E-mail:
laila.klavina@grindeks.lv
|
| Pielikumi |
|